Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Company’s management team will present and host meetings with investors and potential partners next week at the H.C. Wainwright BioConnect Conference,
January 5, 2021
· 4 min read